ArticleThe Journal of clinical investigation2006
cIAP2 is a ubiquitin protein ligase for BCL10 and is dysregulated in mucosa-associated lymphoid tissue lymphomas.
Article in The Journal of clinical investigation, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 100 citations in OpenAlex.
- LUBAC modulates CBM complex functions downstream of TRAF6 in T cells.Nature communications · 2025Article
- Regulation of programmed cell death by Brd4.Cell death & disease · 2022Review
- Signaling through polymerization and degradation: Analysis and simulations of T cell activation mediated by Bcl10.PLoS computational biology · 2021Article
- TRIM41 is required to innate antiviral response by polyubiquitinating BCL10 and recruiting NEMO.Signal transduction and targeted therapy · 2021Article
- CARD19, the protein formerly known as BinCARD, is a mitochondrial protein that does not regulate Bcl10-dependent NF-κB activation after TCR engagement.Cellular immunology · 2020Article
- Targeting BCL10 by small peptides for the treatment of B cell lymphoma.Theranostics · 2020Article
- Article
- CARD-BCL-10-MALT1 signalling in protective and pathological immunity.Nature reviews. Immunology · 2019Review
- MALT1-Deficient Mice Develop Atopic-Like Dermatitis Upon Aging.Frontiers in immunology · 2019Article
- MALT1 Proteolytic Activity Suppresses Autoimmunity in a T Cell Intrinsic Manner.Frontiers in immunology · 2019Article
- Molecular architecture and regulation of BCL10-MALT1 filaments.Nature communications · 2018Article
- Transformation of mouse T cells requires MYC and AKT activity in conjunction with inhibition of intrinsic apoptosis.Oncotarget · 2018Article
- Caspase-10: a molecular switch from cell-autonomous apoptosis to communal cell death in response to chemotherapeutic drug treatment.Cell death and differentiation · 2018Article
- BCL10 - Bridging CARDs to Immune Activation.Frontiers in immunology · 2018Review
- Post-translational Modifications of the CARMA1-BCL10-MALT1 Complex in Lymphocytes and Activated B-Cell Like Subtype of Diffuse Large B-Cell Lymphoma.Frontiers in oncology · 2018Review
- Recent advances in understanding the biology of marginal zone lymphoma.F1000Research · 2018Review
- Clinical utility of recently identified diagnostic, prognostic, and predictive molecular biomarkers in mature B-cell neoplasms.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2017Review
- Autophagy-Mediated Degradation of IAPs and c-FLIP(L) Potentiates Apoptosis Induced by Combination of TRAIL and Chal-24.Journal of cellular biochemistry · 2016Article
- API2-MALT1 oncoprotein promotes lymphomagenesis via unique program of substrate ubiquitination and proteolysis.World journal of biological chemistry · 2016Review
- Article
Corrections and comments
- Commented on by
Authors and funding
13 authors at 1 institution in 1 country.
Funding
Abstract
The pathogenesis of mucosa-associated lymphoid tissue (MALT) lymphomas is associated with independent chromosomal translocations that lead to the upregulation of either BCL10 or MALT1 or the generation of a fusion protein, cIAP2-MALT1. While both BCL10 and MALT1 are critically involved in antigen receptor-mediated NF-kappaB activation, the role of cIAP2 is not clear. Here we show that cIAP2 is a ubiquitin ligase (E3) of BCL10 and targets it for degradation, inhibiting antigen receptor-mediated cytokine production. cIAP2-MALT1 lacks E3 activity, and concomitantly, the BCL10 protein is stabilized in MALT lymphomas harboring this fusion. Furthermore, BCL10 and cIAP2-MALT1 synergistically activate NF-kappaB. These results reveal cIAP2 as an inhibitor of antigenic signaling and implicate its dysfunction in MALT lymphomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.